Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Buy
59
BOUT Quote, Financials, Valuation and Earnings
Last price:
$40.29
Seasonality move
:
1.49%
Day range:
$39.10 - $40.19
52-week range:
$31.48 - $42.41
Dividend yield:
1.11%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
5.4K
Avg. volume:
3.3K
1-year change:
21.42%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BOUT
Innovator IBD Breakout Opportunities ETF
|
-- | -- | -- | -- | -- |
|
FAD
First Trust Multi Cap Growth AlphaDEX Fund
|
-- | -- | -- | -- | -- |
|
FFTY
Innovator IBD 50 ETF
|
-- | -- | -- | -- | -- |
|
IMCG
iShares Morningstar Mid-Cap Growth ETF
|
-- | -- | -- | -- | -- |
|
IWP
iShares Russell Mid-Cap Growth ETF
|
-- | -- | -- | -- | -- |
|
TMFX
Motley Fool Next Index ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BOUT
Innovator IBD Breakout Opportunities ETF
|
$39.85 | -- | -- | -- | $0.01 | 1.11% | -- |
|
FAD
First Trust Multi Cap Growth AlphaDEX Fund
|
$140.42 | -- | -- | -- | $0.31 | 0.58% | -- |
|
FFTY
Innovator IBD 50 ETF
|
$29.84 | -- | -- | -- | $0.16 | 0.53% | -- |
|
IMCG
iShares Morningstar Mid-Cap Growth ETF
|
$76.88 | -- | -- | -- | $0.17 | 0.77% | -- |
|
IWP
iShares Russell Mid-Cap Growth ETF
|
$129.90 | -- | -- | -- | $0.12 | 0.39% | -- |
|
TMFX
Motley Fool Next Index ETF
|
$19.89 | -- | -- | -- | $0.01 | 0.06% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BOUT
Innovator IBD Breakout Opportunities ETF
|
-- | 1.488 | -- | -- |
|
FAD
First Trust Multi Cap Growth AlphaDEX Fund
|
-- | 1.412 | -- | -- |
|
FFTY
Innovator IBD 50 ETF
|
-- | 1.958 | -- | -- |
|
IMCG
iShares Morningstar Mid-Cap Growth ETF
|
-- | 1.316 | -- | -- |
|
IWP
iShares Russell Mid-Cap Growth ETF
|
-- | 1.344 | -- | -- |
|
TMFX
Motley Fool Next Index ETF
|
-- | 1.388 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BOUT
Innovator IBD Breakout Opportunities ETF
|
-- | -- | -- | -- | -- | -- |
|
FAD
First Trust Multi Cap Growth AlphaDEX Fund
|
-- | -- | -- | -- | -- | -- |
|
FFTY
Innovator IBD 50 ETF
|
-- | -- | -- | -- | -- | -- |
|
IMCG
iShares Morningstar Mid-Cap Growth ETF
|
-- | -- | -- | -- | -- | -- |
|
IWP
iShares Russell Mid-Cap Growth ETF
|
-- | -- | -- | -- | -- | -- |
|
TMFX
Motley Fool Next Index ETF
|
-- | -- | -- | -- | -- | -- |
Innovator IBD Breakout Opportunities ETF vs. Competitors
-
Which has Higher Returns BOUT or FAD?
First Trust Multi Cap Growth AlphaDEX Fund has a net margin of -- compared to Innovator IBD Breakout Opportunities ETF's net margin of --. Innovator IBD Breakout Opportunities ETF's return on equity of -- beat First Trust Multi Cap Growth AlphaDEX Fund's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BOUTInnovator IBD Breakout Opportunities ETF-- -- -- FADFirst Trust Multi Cap Growth AlphaDEX Fund-- -- -- -
What do Analysts Say About BOUT or FAD?
Innovator IBD Breakout Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Multi Cap Growth AlphaDEX Fund has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovator IBD Breakout Opportunities ETF has higher upside potential than First Trust Multi Cap Growth AlphaDEX Fund, analysts believe Innovator IBD Breakout Opportunities ETF is more attractive than First Trust Multi Cap Growth AlphaDEX Fund.
Company Buy Ratings Hold Ratings Sell Ratings BOUTInnovator IBD Breakout Opportunities ETF0 0 0 FADFirst Trust Multi Cap Growth AlphaDEX Fund0 0 0 -
Is BOUT or FAD More Risky?
Innovator IBD Breakout Opportunities ETF has a beta of 0.983, which suggesting that the stock is 1.707% less volatile than S&P 500. In comparison First Trust Multi Cap Growth AlphaDEX Fund has a beta of 1.124, suggesting its more volatile than the S&P 500 by 12.411%.
-
Which is a Better Dividend Stock BOUT or FAD?
Innovator IBD Breakout Opportunities ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 1.11%. First Trust Multi Cap Growth AlphaDEX Fund offers a yield of 0.58% to investors and pays a quarterly dividend of $0.31 per share. Innovator IBD Breakout Opportunities ETF pays -- of its earnings as a dividend. First Trust Multi Cap Growth AlphaDEX Fund pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOUT or FAD?
Innovator IBD Breakout Opportunities ETF quarterly revenues are --, which are smaller than First Trust Multi Cap Growth AlphaDEX Fund quarterly revenues of --. Innovator IBD Breakout Opportunities ETF's net income of -- is lower than First Trust Multi Cap Growth AlphaDEX Fund's net income of --. Notably, Innovator IBD Breakout Opportunities ETF's price-to-earnings ratio is -- while First Trust Multi Cap Growth AlphaDEX Fund's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovator IBD Breakout Opportunities ETF is -- versus -- for First Trust Multi Cap Growth AlphaDEX Fund. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOUTInnovator IBD Breakout Opportunities ETF-- -- -- -- FADFirst Trust Multi Cap Growth AlphaDEX Fund-- -- -- --
-
Which has Higher Returns BOUT or FFTY?
Innovator IBD 50 ETF has a net margin of -- compared to Innovator IBD Breakout Opportunities ETF's net margin of --. Innovator IBD Breakout Opportunities ETF's return on equity of -- beat Innovator IBD 50 ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BOUTInnovator IBD Breakout Opportunities ETF-- -- -- FFTYInnovator IBD 50 ETF-- -- -- -
What do Analysts Say About BOUT or FFTY?
Innovator IBD Breakout Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Innovator IBD 50 ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovator IBD Breakout Opportunities ETF has higher upside potential than Innovator IBD 50 ETF, analysts believe Innovator IBD Breakout Opportunities ETF is more attractive than Innovator IBD 50 ETF.
Company Buy Ratings Hold Ratings Sell Ratings BOUTInnovator IBD Breakout Opportunities ETF0 0 0 FFTYInnovator IBD 50 ETF0 0 0 -
Is BOUT or FFTY More Risky?
Innovator IBD Breakout Opportunities ETF has a beta of 0.983, which suggesting that the stock is 1.707% less volatile than S&P 500. In comparison Innovator IBD 50 ETF has a beta of 1.186, suggesting its more volatile than the S&P 500 by 18.613%.
-
Which is a Better Dividend Stock BOUT or FFTY?
Innovator IBD Breakout Opportunities ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 1.11%. Innovator IBD 50 ETF offers a yield of 0.53% to investors and pays a quarterly dividend of $0.16 per share. Innovator IBD Breakout Opportunities ETF pays -- of its earnings as a dividend. Innovator IBD 50 ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOUT or FFTY?
Innovator IBD Breakout Opportunities ETF quarterly revenues are --, which are smaller than Innovator IBD 50 ETF quarterly revenues of --. Innovator IBD Breakout Opportunities ETF's net income of -- is lower than Innovator IBD 50 ETF's net income of --. Notably, Innovator IBD Breakout Opportunities ETF's price-to-earnings ratio is -- while Innovator IBD 50 ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovator IBD Breakout Opportunities ETF is -- versus -- for Innovator IBD 50 ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOUTInnovator IBD Breakout Opportunities ETF-- -- -- -- FFTYInnovator IBD 50 ETF-- -- -- --
-
Which has Higher Returns BOUT or IMCG?
iShares Morningstar Mid-Cap Growth ETF has a net margin of -- compared to Innovator IBD Breakout Opportunities ETF's net margin of --. Innovator IBD Breakout Opportunities ETF's return on equity of -- beat iShares Morningstar Mid-Cap Growth ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BOUTInnovator IBD Breakout Opportunities ETF-- -- -- IMCGiShares Morningstar Mid-Cap Growth ETF-- -- -- -
What do Analysts Say About BOUT or IMCG?
Innovator IBD Breakout Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Morningstar Mid-Cap Growth ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovator IBD Breakout Opportunities ETF has higher upside potential than iShares Morningstar Mid-Cap Growth ETF, analysts believe Innovator IBD Breakout Opportunities ETF is more attractive than iShares Morningstar Mid-Cap Growth ETF.
Company Buy Ratings Hold Ratings Sell Ratings BOUTInnovator IBD Breakout Opportunities ETF0 0 0 IMCGiShares Morningstar Mid-Cap Growth ETF0 0 0 -
Is BOUT or IMCG More Risky?
Innovator IBD Breakout Opportunities ETF has a beta of 0.983, which suggesting that the stock is 1.707% less volatile than S&P 500. In comparison iShares Morningstar Mid-Cap Growth ETF has a beta of 1.094, suggesting its more volatile than the S&P 500 by 9.359%.
-
Which is a Better Dividend Stock BOUT or IMCG?
Innovator IBD Breakout Opportunities ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 1.11%. iShares Morningstar Mid-Cap Growth ETF offers a yield of 0.77% to investors and pays a quarterly dividend of $0.17 per share. Innovator IBD Breakout Opportunities ETF pays -- of its earnings as a dividend. iShares Morningstar Mid-Cap Growth ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOUT or IMCG?
Innovator IBD Breakout Opportunities ETF quarterly revenues are --, which are smaller than iShares Morningstar Mid-Cap Growth ETF quarterly revenues of --. Innovator IBD Breakout Opportunities ETF's net income of -- is lower than iShares Morningstar Mid-Cap Growth ETF's net income of --. Notably, Innovator IBD Breakout Opportunities ETF's price-to-earnings ratio is -- while iShares Morningstar Mid-Cap Growth ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovator IBD Breakout Opportunities ETF is -- versus -- for iShares Morningstar Mid-Cap Growth ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOUTInnovator IBD Breakout Opportunities ETF-- -- -- -- IMCGiShares Morningstar Mid-Cap Growth ETF-- -- -- --
-
Which has Higher Returns BOUT or IWP?
iShares Russell Mid-Cap Growth ETF has a net margin of -- compared to Innovator IBD Breakout Opportunities ETF's net margin of --. Innovator IBD Breakout Opportunities ETF's return on equity of -- beat iShares Russell Mid-Cap Growth ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BOUTInnovator IBD Breakout Opportunities ETF-- -- -- IWPiShares Russell Mid-Cap Growth ETF-- -- -- -
What do Analysts Say About BOUT or IWP?
Innovator IBD Breakout Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand iShares Russell Mid-Cap Growth ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovator IBD Breakout Opportunities ETF has higher upside potential than iShares Russell Mid-Cap Growth ETF, analysts believe Innovator IBD Breakout Opportunities ETF is more attractive than iShares Russell Mid-Cap Growth ETF.
Company Buy Ratings Hold Ratings Sell Ratings BOUTInnovator IBD Breakout Opportunities ETF0 0 0 IWPiShares Russell Mid-Cap Growth ETF0 0 0 -
Is BOUT or IWP More Risky?
Innovator IBD Breakout Opportunities ETF has a beta of 0.983, which suggesting that the stock is 1.707% less volatile than S&P 500. In comparison iShares Russell Mid-Cap Growth ETF has a beta of 1.119, suggesting its more volatile than the S&P 500 by 11.906%.
-
Which is a Better Dividend Stock BOUT or IWP?
Innovator IBD Breakout Opportunities ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 1.11%. iShares Russell Mid-Cap Growth ETF offers a yield of 0.39% to investors and pays a quarterly dividend of $0.12 per share. Innovator IBD Breakout Opportunities ETF pays -- of its earnings as a dividend. iShares Russell Mid-Cap Growth ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOUT or IWP?
Innovator IBD Breakout Opportunities ETF quarterly revenues are --, which are smaller than iShares Russell Mid-Cap Growth ETF quarterly revenues of --. Innovator IBD Breakout Opportunities ETF's net income of -- is lower than iShares Russell Mid-Cap Growth ETF's net income of --. Notably, Innovator IBD Breakout Opportunities ETF's price-to-earnings ratio is -- while iShares Russell Mid-Cap Growth ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovator IBD Breakout Opportunities ETF is -- versus -- for iShares Russell Mid-Cap Growth ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOUTInnovator IBD Breakout Opportunities ETF-- -- -- -- IWPiShares Russell Mid-Cap Growth ETF-- -- -- --
-
Which has Higher Returns BOUT or TMFX?
Motley Fool Next Index ETF has a net margin of -- compared to Innovator IBD Breakout Opportunities ETF's net margin of --. Innovator IBD Breakout Opportunities ETF's return on equity of -- beat Motley Fool Next Index ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BOUTInnovator IBD Breakout Opportunities ETF-- -- -- TMFXMotley Fool Next Index ETF-- -- -- -
What do Analysts Say About BOUT or TMFX?
Innovator IBD Breakout Opportunities ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Motley Fool Next Index ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that Innovator IBD Breakout Opportunities ETF has higher upside potential than Motley Fool Next Index ETF, analysts believe Innovator IBD Breakout Opportunities ETF is more attractive than Motley Fool Next Index ETF.
Company Buy Ratings Hold Ratings Sell Ratings BOUTInnovator IBD Breakout Opportunities ETF0 0 0 TMFXMotley Fool Next Index ETF0 0 0 -
Is BOUT or TMFX More Risky?
Innovator IBD Breakout Opportunities ETF has a beta of 0.983, which suggesting that the stock is 1.707% less volatile than S&P 500. In comparison Motley Fool Next Index ETF has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BOUT or TMFX?
Innovator IBD Breakout Opportunities ETF has a quarterly dividend of $0.01 per share corresponding to a yield of 1.11%. Motley Fool Next Index ETF offers a yield of 0.06% to investors and pays a quarterly dividend of $0.01 per share. Innovator IBD Breakout Opportunities ETF pays -- of its earnings as a dividend. Motley Fool Next Index ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BOUT or TMFX?
Innovator IBD Breakout Opportunities ETF quarterly revenues are --, which are smaller than Motley Fool Next Index ETF quarterly revenues of --. Innovator IBD Breakout Opportunities ETF's net income of -- is lower than Motley Fool Next Index ETF's net income of --. Notably, Innovator IBD Breakout Opportunities ETF's price-to-earnings ratio is -- while Motley Fool Next Index ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Innovator IBD Breakout Opportunities ETF is -- versus -- for Motley Fool Next Index ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BOUTInnovator IBD Breakout Opportunities ETF-- -- -- -- TMFXMotley Fool Next Index ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
NVIDIA vs Broadcom Stock: Which Is Best?
If you want to invest in an AI-leading tech company,…
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 3.65% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 4.9% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 4.4% over the past day.
